UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 29, 2022
MaxCyte, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 001-40674 | 52-2210438 |
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
22 Firstfield Road, Suite 110
Gaithersburg, Maryland 20878
(Address of principal executive offices, including zip code)
(301) 944-1700
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| Common Stock, $0.01 par value | MXCT | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
The Board of Directors (the “Board”) of MaxCyte, Inc. (the “Company”) adopted the MaxCyte, Inc. 2022 Equity Incentive Plan (the “2022 Plan”) on May 22, 2022 and submitted the 2022 Plan for stockholder approval at the 2022 Annual Meeting of Stockholders of the Company on June 29, 2022 (the “Annual Meeting”). As described in Item 5.07 below, the Company’s stockholders approved the 2022 Plan at the Annual Meeting, including the reservation of shares of the Company’s common stock for issuance thereunder.
A summary of the 2022 Plan is set forth in the Company’s definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on May 26, 2022 (the “Proxy Statement”).
The description of the terms of the 2022 Plan contained herein and in the Proxy Statement is qualified in its entirety by the text of the 2022 Plan, a copy of which is attached as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference herein.
Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 29, 2022, the Company held the Annual Meeting. The stockholders considered three proposals, each of which is described in more detail in the Proxy Statement. Of the 101,540,052 shares outstanding as of the record date, 71,569,005 shares, or 70.48%, were present or represented by proxy at the Annual Meeting. Set forth below are the results of the matters submitted for a vote of stockholders at the Annual Meeting.
Proposal No. 1: Election of three nominees to serve as directors until the 2025 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows:
| Name | Votes For | Votes Withheld | ||||||
| Doug Doerfler | 41,284,606 | 25,053,467 | ||||||
| Yasir Al-Wakeel, BM BCh | 40,978,094 | 25,359,979 | ||||||
| Rekha Hemrajani | 49,463,609 | 16,874,464 | ||||||
Broker Non-Votes: 5,230,932
All nominees were elected.
Proposal No. 2: Approval of the 2022 Plan. The votes were cast as follows:
| Votes For | Votes Against | Abstained | ||||||||||
| Approval of the Company’s 2022 Equity Incentive Plan | 58,325,256 | 8,001,599 | 11,218 | |||||||||
Broker Non-Votes: 5,230,932
Proposal No. 3: Ratification of the appointment of CohnReznick LLP as independent registered public accounting firm for the fiscal year ending December 31, 2022. The votes were cast as follows:
| Votes For | Votes Against | Abstained | ||||||||||
| Ratification of appointment of CohnReznick LLP | 71,552,677 | 8,475 | 7,853 | |||||||||
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit | ||
| Number | Exhibit Description | |
| 10.1 | MaxCyte, Inc. 2022 Equity Incentive Plan. | |
| 104 | Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| MaxCyte, Inc. | ||
| Dated: June 30, 2022 | By: | /s/ Doug Doerfler |
| Doug Doerfler | ||
| President and Chief Executive Officer | ||